P3 Therapeutics
All news
/Company

Advancing Preclinical Partnerships and Seed Financing - P3 Therapeutics Participates in BIO-Europe 2026 in Cologne

P3 Therapeutics attended BIO-Europe 2026 in Cologne on 9–11 November, presenting our multi-target small molecules and organ-on-chip testing strategy for spondyloarthritis and IBD to biopharma executives and investors.

P3Therapeutics at BIO-Europe 2026 in Cologne

Zagreb, Croatia — November 2026 — The P3 Therapeutics (P3T) team attended BIO-Europe 2026, Europe’s premier life sciences partnering conference, held from November 9–11, 2026, at Koelnmesse in Cologne, Germany. 

Across three days of intensive one-on-one partnering sessions, the team engaged with global biopharma executives, R&D leaders, and life sciences investors to showcase P3T’s differentiated approach to treating chronic immune-mediated inflammatory diseases (IMIDs). 

BIO-Europe provided an invaluable platform to discuss how P3T multi-target small molecules and organ-on-chip testing strategy address major unmet needs in spondyloarthritis and IBD. 

We thank everyone who met with us in Cologne and look forward to continuing these conversations as our preclinical data matures.

For partnering inquiries, licensing discussions, or investor information, please contact the P3 Therapeutics team at info@p3therapeutics.eu or visit p3therapeutics.eu.